DB08815ApprovedInvestigationalSmall moleculeAntipsychotic AgentsAntipsychotic Agents (Second Generation [Atypical])
Lurasidone is an atypical antipsychotic used to treat schizophrenia and depressive episodes associated with bipolar I disorder. Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma.
- Mechanism
- Curator reviewed
Lurasidone is an atypical antipsychotic that is a D2 and 5-HT2A (mixed serotonin and dopamine activity) to improve cognition. It is thought that antagonism of serotonin receptors can improve negative symptoms of psychoses and reduce the extrapyramidal side effects that are often associated with typical antipsychotics.
- Primary indication
- Lurasidone is indicated for the treatment of schizophrenia in patients ≥13 years old.Curator reviewed · 4 structured indications
- Formula / weight
- C28H36N4O2S · 492.676 g/mol (avg)
- First approval
- Canada, 2022 · United States, 2010 · European Union, 2020
- Code names
- SM-13496
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
PQXKDMSYBGKCJA-CVTJIBDQSA-NSMILES[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=OWhat you can answer from here — as of September 23, 2026
6Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Lurasidone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account